Stealthy biotech firm Aviir just raised a $7.8 million bridge round of financing to last it through the rest of 2009, according to VentureWire. Based in Palo Alto, Calif., the company hasn't released much information about its actual products -- only that its methods may eventually be used to detect early warning signs of heart disease, heart attacks or strokes on the molecular level.
Born out of research conducted in Stanford University labs, the technology will be ready to go to market sometime in the next two years, according to the company's web site. To make this a reality, Aviir will look to raise more money before the year is out.
Investors in the recent round are Aberdare Ventures, Bay City Capital and New Leaf Venture Partners. It last raised funds in March amounting to $1.5 million.